SCYNEXIS INC
SCYX$74.95T
Mega CapNASDAQPharmaceutical Preparations🇺🇸North AmericaJERSEY CITY
Drugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
SCYX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
SCY-078
Mycoses
Ibrexafungerp
Candida Vulvovaginitis
Fluconazole Tablet
Recurrent Vulvovaginal Candidiasis
SCY-635
Hepatitis C Infection
Fluconazole
Vulvovaginal Candidiasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SCY-078 | Phase 3 | Mycoses | - | - |
Ibrexafungerp | Phase 3 | Candida Vulvovaginitis | - | - |
Fluconazole Tablet | Phase 3 | Recurrent Vulvovaginal Candidiasis | - | - |
SCY-635 | Phase 2 | Hepatitis C Infection | - | - |
Fluconazole | Phase 2 | Vulvovaginal Candidiasis | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply